Pieter Dylst1, Steven Simoens. 1. Research Centre for Pharmaceutical Care & Pharmaco-economics, K.U.Leuven, Belgium. pieter.dylst@pharm.kuleuven.be
Abstract
BACKGROUND: After the expiry of patents for originator medicines, generic medicines can enter the market, and price competition may occur. This process generates savings to the healthcare payer and to patients, but knowledge about the factors affecting price competition in the pharmaceutical market following patent expiry is still limited. OBJECTIVE: This study aimed to investigate the relationship between the market share of generic medicines and the change of the medicine price level in European off-patent markets. METHODS: Data on medicine volumes and values for 35 active substances were purchased from IMS Health. Ex-manufacturer prices were used, and the analysis was limited to medicines in immediate-release, oral, solid dosage forms. Countries included were Austria, Belgium, Denmark, Germany, France, Italy, the Netherlands, Spain, Sweden and the UK, which constitute a mix of countries with low and high generic medicines market shares. Data were available from June 2002 until March 2007. RESULTS: Market volume has risen in both high and low generic market share countries (+29.27% and +27.40%, respectively), but the cause of the rise is different for the two markets. In low generic market share countries, the rise was caused by the increased use of generic medicines, while in high market share countries, the rise was driven by the increased use of generic medicines and a shift of use from originator to generic medicines. Market value was substantially decreased in high generic market share countries (-26.6%), while the decrease in low generic market share countries was limited (-0.06%). In high generic market share countries, medicine prices dropped by -43.18% versus -21.56% in low market share countries. CONCLUSIONS: The extent to which price competition from generic medicines leads to price reductions appears to vary according to the market share of generic medicines. High generic market share countries have seen a larger decrease in medicine prices than low market share countries.
BACKGROUND: After the expiry of patents for originator medicines, generic medicines can enter the market, and price competition may occur. This process generates savings to the healthcare payer and to patients, but knowledge about the factors affecting price competition in the pharmaceutical market following patent expiry is still limited. OBJECTIVE: This study aimed to investigate the relationship between the market share of generic medicines and the change of the medicine price level in European off-patent markets. METHODS: Data on medicine volumes and values for 35 active substances were purchased from IMS Health. Ex-manufacturer prices were used, and the analysis was limited to medicines in immediate-release, oral, solid dosage forms. Countries included were Austria, Belgium, Denmark, Germany, France, Italy, the Netherlands, Spain, Sweden and the UK, which constitute a mix of countries with low and high generic medicines market shares. Data were available from June 2002 until March 2007. RESULTS: Market volume has risen in both high and low generic market share countries (+29.27% and +27.40%, respectively), but the cause of the rise is different for the two markets. In low generic market share countries, the rise was caused by the increased use of generic medicines, while in high market share countries, the rise was driven by the increased use of generic medicines and a shift of use from originator to generic medicines. Market value was substantially decreased in high generic market share countries (-26.6%), while the decrease in low generic market share countries was limited (-0.06%). In high generic market share countries, medicine prices dropped by -43.18% versus -21.56% in low market share countries. CONCLUSIONS: The extent to which price competition from generic medicines leads to price reductions appears to vary according to the market share of generic medicines. High generic market share countries have seen a larger decrease in medicine prices than low market share countries.
Authors: Catherine Sermet; Veronique Andrieu; Brian Godman; Eric Van Ganse; Alan Haycox; Jean-Pierre Reynier Journal: Appl Health Econ Health Policy Date: 2010 Impact factor: 2.561
Authors: Giorgio L Colombo; Enrico Agabiti-Rosei; Alberto Margonato; Claudio Mencacci; Carlo Maurizio Montecucco; Roberto Trevisan Journal: PLoS One Date: 2013-12-18 Impact factor: 3.240
Authors: F Mattioli; G Siri; F Castelli; M Puntoni; M L Zuccoli; A Stimamiglio; A Martelli Journal: Patient Prefer Adherence Date: 2017-08-18 Impact factor: 2.711
Authors: Pieter J Glerum; Yang Yu; Walter M Yamada; Michael N Neely; Marc Maliepaard; David M Burger; Cees Neef Journal: Clin Pharmacol Ther Date: 2018-02-13 Impact factor: 6.875